Clearmind Medicine (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, has filed a provisional patent application (“PPA”) with the United States Patent and Trademark Office (“USPTO”). The patent, which was filed on Oct. 8, 2021, covers CMND’s proprietary, novel methods of drug-assisted psychotherapy. According to the company, drug-assisted psychotherapy combines drug and psychological treatments designed to create a superior outcome when used together, including an improved patient-therapist relationship and increased flexibility in the patient’s mind, which allows a patient to explore new methods of treatment. “This filing is another marker in our commitment to build value by establishing a best-in-class IP portfolio to include novel molecules, delivery mechanisms, processes and protocols,” said Clearmind Medicine CEO Adi Zuloff-Shani, PhD, in the press release. “These discoveries reflect the dedication, innovation and creativity at the heart of our research and development team, and position us to pursue the substantial market opportunity in the field of psychedelic-based medicine.”
To view the full press release, visit https://ibn.fm/NdZiW
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of two patent families. The first, Binge Behavior Regulators, has been granted in the United States, Europe, China and India, with pending divisional applications in Europe and the U.S. The second, Alcohol Beverage Substitute, has been approved for a European patent, with pending applications in the U.S., China and India. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. To learn more about the company, please visit www.ClearmindMedicine.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.